2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024, 86: 516-527. PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer experts
2023
An overview of novel therapies in advanced clinical testing for acute myeloid leukemia
Venugopal S, Xie Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Review Of Hematology 2023, 16: 109-119. PMID: 36718500, DOI: 10.1080/17474086.2023.2174521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAML therapyMolecular pathogenesisApproval of midostaurinPathophysiology of AMLMeasurable residual diseaseAdvanced clinical testingClinical trial developmentAcute myeloid leukemiaCell surface antigensDevelopment of agentsDisease relapseImmune environmentAML treatmentResidual diseaseTherapeutic armamentariumMyeloid leukemiaNovel therapiesSurface antigenClinical testingTrial developmentTherapyAMLEscape mechanismsGene mutationsRelapse
2014
Cinacalcet hydrochloride for the treatment of hyperparathyroidism
Sarav M, Sprague S. Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opinion On Orphan Drugs 2014, 2: 851-863. DOI: 10.1517/21678707.2014.940311.Peer-Reviewed Original ResearchSecondary hyperparathyroidismTreatment of secondary hyperparathyroidismComplication of chronic kidney diseaseSevere primary hyperparathyroidismParathyroid hormone excessTreatment of hyperparathyroidismCalcium-sensing receptorChronic kidney diseasePrimary hyperparathyroidismCalcimimetic agentHormone excessDevelopment of agentsSafety profileClinical efficacyG protein-coupled receptorsClinical indicationsCalcium metabolismDialysis patientsHyperparathyroidismKidney diseaseCaSRCinacalcetCinacalcet hydrochlorideCalcimimeticsReceptors
2013
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
Zardavas D, Cameron D, Krop I, Piccart M. Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer . American Society Of Clinical Oncology Educational Book 2013, 33: e2-e11. PMID: 23714441, DOI: 10.1200/edbook_am.2013.33.e2.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsChemotherapy, AdjuvantDrug Resistance, NeoplasmFemaleHumansLapatinibMolecular Targeted TherapyNeoadjuvant TherapyProtein Kinase InhibitorsQuinazolinesReceptor, ErbB-2Signal TransductionTrastuzumabTreatment OutcomeConceptsHER2-positive breast cancerDual HER2 blockadeAntibody-drug conjugatesHER2 blockadeBreast cancerMetastatic settingClinical trialsAnti-HER2 resistanceAnti-HER2 agentsLarge randomized trialsHER2-targeted agentsNew treatment optionsAggressive biologic behaviorMajor clinical issueImproved treatment outcomesNew therapeutic avenuesDevelopment of agentsAdjuvant settingNeoadjuvant settingAdvanced diseaseTrastuzumab-DM1Randomized trialsTreatment optionsBiologic rationaleHER2 inhibition
2011
The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion
Chin A, Svejda B, Gustafsson B, Granlund A, Sandvik A, Timberlake A, Sumpio B, Pfragner R, Modlin I, Kidd M. The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. AJP Gastrointestinal And Liver Physiology 2011, 302: g397-g405. PMID: 22038827, PMCID: PMC3287403, DOI: 10.1152/ajpgi.00087.2011.Peer-Reviewed Original ResearchMeSH KeywordsAcetamidesAdenosineAdenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsAdenosine-5'-(N-ethylcarboxamide)AdultAgedCell Line, TumorCells, CulturedColonCrohn DiseaseCyclic AMPCyclic AMP Response Element-Binding ProteinCyclic AMP-Dependent Protein KinasesEnterochromaffin CellsFemaleGene ExpressionHumansMaleMAP Kinase Kinase 1MAP Kinase Signaling SystemMechanotransduction, CellularMiddle AgedPhosphorylationProto-Oncogene Proteins c-aktPurinesReceptor, Adenosine A1Receptor, Adenosine A2AReceptor, Adenosine A2BReceptor, Adenosine A3SerotoninSignal TransductionStress, MechanicalTryptophan HydroxylaseVesicular Monoamine Transport ProteinsConceptsInflammatory bowel diseaseEC cellsCell functionEC cell functionMechanical stimulationDevelopment of agentsSecrete serotoninBowel diseaseIntracellular cAMP levelsGut motilityEnterochromaffin cellsAdenosine responsivenessReceptor agonistReceptor expressionHuman EC cellsSerotonin secretionAdenosine receptorsMRS1754CAMP productionSecretionCAMP levelsNECANeoplasiaMechanosensory cellsDisease
2007
CTGF, intestinal stellate cells and carcinoid fibrogenesis
Kidd M, Modlin I, Shapiro M, Camp R, Mane S, Usinger W, Murren J. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World Journal Of Gastroenterology 2007, 13: 5208-5216. PMID: 17876891, PMCID: PMC4171302, DOI: 10.3748/wjg.v13.i39.5208.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoid TumorCase-Control StudiesCells, CulturedConnective Tissue Growth FactorExtracellular MatrixFemaleFibrosisGastrointestinal NeoplasmsHumansImmediate-Early ProteinsIntercellular Signaling Peptides and ProteinsIntestine, SmallMaleMiddle AgedRNA, MessengerTissue Array AnalysisTransforming Growth Factor beta1ConceptsCarcinoid tumor patientsStellate cellsCarcinoid tumorsTumor patientsTissue microarrayGI carcinoid tumorsDevelopment of agentsGI carcinoidsPlasma CTGFSerum CTGFSystemic complicationsFibrotic mediatorsGastric carcinoidsHistological fibrosisPeritoneal fibrosisNormal mucosaTumor fibrosisFibrotic responseFibrosisFibrotic tissueRT-PCR analysisCTGFTGFbeta1Q-RT-PCR analysisSandwich ELISA
2002
Targeted therapy in non-small-cell lung cancer.
Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology 2002, 16: 19-24. PMID: 12375797.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials as TopicEndothelial Growth FactorsErbB ReceptorsHumansIntercellular Signaling Peptides and ProteinsLung NeoplasmsLymphokinesProtein Kinase CVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsCell lung cancerLung cancerSuch new agentsNew agentsVascular endothelial growth factor inhibitorsPlatinum-based combination therapyEGFR tyrosine kinase inhibitorsGrowth factor receptor inhibitorsNew biologic therapiesGrowth factor inhibitorsEpithelial growth factor receptor inhibitorTyrosine kinase inhibitorsSpecific biologic pathwaysDevelopment of agentsSignal transduction inhibitorsMaintenance therapyBiologic therapyCytotoxic chemotherapyStages of treatmentFactor inhibitorsCombination therapyTargeted therapyReceptor inhibitorsRadiation therapyClinical investigation
1999
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs
Zhang X, Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorganic & Medicinal Chemistry Letters 1999, 9: 3193-3198. PMID: 10576686, DOI: 10.1016/s0960-894x(99)00561-2.Peer-Reviewed Original Research
1996
In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate.
Yoshida D, Piepmeier J, Teramoto A. In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate. Neurosurgery 1996, 39: 360-6. PMID: 8832674, DOI: 10.1097/00006123-199608000-00025.Peer-Reviewed Original ResearchConceptsEstramustine phosphateMumol/LGlioblastoma cell linesCell proliferationRelative survival ratesTreatment of glioblastomaCell linesTime-dependent depressionAnti-invasive abilityDevelopment of agentsHuman glioblastoma cell linesU87MG human glioblastoma cellsHuman glioblastoma cellsSurvival rateTumor proliferationDrug concentrationsMonotetrazolium assayAntiproliferative capacityCell invasivenessGlioblastoma cellsNon-DNA targetsBasement membraneInvasion indexInvasive potentialSelective antiproliferative activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply